Alzamend Neuro(ALZN.US)：2023年Q3财报实现营收0美元

证券之星2023-03-16

Alzamend Neuro(ALZN.US)：2023年Q3财报实现营收0美元，前值为0美元；每股收益为-0.06美元，前值为-0.03美元，预期值为-0.04美元，比市场预期低50.00%。Alzamend Neuro（ALZN.US）公司简介：Alzamend Neuro Inc是一家早期临床阶段的生物制药公司。它专注于开发用于治疗神经退行性疾病和包括阿尔茨海默氏症在内的精神疾病的新产品。它...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2319363909?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-03-16 22:05","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2319363909","market":"us","top_or_hot":-1,"title":"Alzamend Neuro(ALZN.US)：2023年Q3财报实现营收0美元","media":"证券之星","content":"<div>\n<p>Alzamend Neuro(ALZN.US)：2023年Q3财报实现营收0美元，前值为0美元；每股收益为-0.06美元，前值为-0.03美元，预期值为-0.04美元，比市场预期低50.00%。Alzamend Neuro（ALZN.US）公司简介：Alzamend Neuro Inc是一家早期临床阶段的生物制药公司。它专注于开发用于治疗神经退行性疾病和包括阿尔茨海默氏症在内的精神疾病的新产品。它...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230316221547826bf701&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alzamend Neuro(ALZN.US)：2023年Q3财报实现营收0美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlzamend Neuro(ALZN.US)：2023年Q3财报实现营收0美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-16 22:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230316221547826bf701&s=b><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alzamend Neuro(ALZN.US)：2023年Q3财报实现营收0美元，前值为0美元；每股收益为-0.06美元，前值为-0.03美元，预期值为-0.04美元，比市场预期低50.00%。Alzamend Neuro（ALZN.US）公司简介：Alzamend Neuro Inc是一家早期临床阶段的生物制药公司。它专注于开发用于治疗神经退行性疾病和包括阿尔茨海默氏症在内的精神疾病的新产品。它...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230316221547826bf701&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALZN","symbol_name":"Alzamend Neuro, Inc","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230316221547826bf701&s=b","article_id":"2319363909","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230316221547826bf701&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2319363909","pubTimestamp":1678975539,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Alzamend Neuro：2023年Q3财报实现营收0美元，前值为0美元；每股收益为-0.06美元，前值为-0.03美元，预期值为-0.04美元，比市场预期低50.00%。Alzamend Neuro公司简介：Alzamend Neuro Inc是一家早期临床阶段的生物制药公司。它专注于开发用于治疗神经退行性疾病和包括阿尔茨海默氏症在内的精神疾病的新产品。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ALZN":"Alzamend Neuro, Inc"},"translate_title":"Alzamend Neuro (ALZN.US): The Q3 financial report in 2023 achieved revenue of 0 US dollars","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALZN":0.9},"content_text":"Alzamend Neuro(ALZN.US)：2023年Q3财报实现营收0美元，前值为0美元；每股收益为-0.06美元，前值为-0.03美元，预期值为-0.04美元，比市场预期低50.00%。Alzamend Neuro（ALZN.US）公司简介：Alzamend Neuro Inc是一家早期临床阶段的生物制药公司。它专注于开发用于治疗神经退行性疾病和包括阿尔茨海默氏症在内的精神疾病的新产品。它的使命是开发和销售安全有效的治疗方法。该公司的产品线包括两种新型的治疗性候选药物AL001——一种专利离子共晶体技术，通过锂、脯氨酸和水杨酸盐的治疗性组合来传递锂，AL002是一种使用突变肽致敏细胞作为基于细胞的治疗性疫苗的专利方法，寻求恢复患者免疫系统的能力，以对抗阿尔茨海默氏症。以上内容由证券之星根据公开信息整理，与本站立场无关。证券之星力求但不保证该信息（包括但不限于文字、视频、音频、数据及图表）全部或者部分内容的的准确性、完整性、有效性、及时性等，如存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2319363909"}